Author

J. Korkola

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Assay:proteomics· 1

Frequent Co-Authors

A. B. Olshen· 1 shared A. Cheltsov· 1 shared A. Goga· 1 shared A. Nilsen· 1 shared A. Renslo· 1 shared B. C. Hann· 1 shared C. Boniface· 1 shared C. E. Tognon· 1 shared

Activity by Year

2017-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. B. Olshen

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A tumour-promoting senescent secretome triggered by platinum chemotherapy exploits a targetable TGFβR1/Akt-mTOR axis in lung cancer

E. Gonzalez-Gualda, D. Macias, S. Morsli, E. Martin, H.-L. Ou, M. Denholm, I. Olan, R. Hoffmann, M. Dane, D. Veroutis, G. Medrano, F. Mulero, C. Martins, M. Barbacid, V. Gorgoulis, , D. Munoz-Espin

This study shows platinum chemotherapy induces a senescent secretome in lung cancer that promotes tumor growth via the TGFβR1/Akt-mTOR axis, and targeting this pathway reduces tumor burden.

bioRxiv · Aug 1, 2022 · PreprintCancer Biology

Exploiting KRAS-driven Ferroaddiction in Cancer Through Ferrous Iron-Activatable Drug Conjugates (FeADC)

H. Jiang, R. K. Muir, R. L. Gonciarz, A. B. Olshen, I. Yeh, B. C. Hann, N. Zhao, Y.-h. Wang, J. Korkola, S. C. Behr, M. J. Evans, e. collisson, A. Renslo

This paper develops FeADCs, ferrous iron-activatable drug conjugates, to target KRAS-driven cancers with improved tumor selectivity and systemic tolerability.

bioRxiv · May 12, 2020Cancer Biology

Crosstalk between invadopodia and the extracellular matrix

S. Iizuka, R. P. Leon, K. P. Gribbin, Y. Zhang, J. Navarro, R. Smith, K. Devlin, L. G. Wang, S. L. Gibbs, J. Korkola, X. Nan, S. A. Courtneidge

This study investigates the interaction between invadopodia and the extracellular matrix, showing that Tks5 is involved in matrix-dependent growth and invadopodia formation.

bioRxiv · Feb 26, 2020Cancer Biology

Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity

D. Rozanov, A. Cheltsov, A. Nilsen, C. Boniface, J. Korkola, J. Gray, J. Tyner, C. E. Tognon, G. B. Mills, P. Spellman

The paper identifies key factors distinguishing non-toxic and toxic compounds targeting mitochondria in cancer therapy using SAR studies and a mathematical model.

bioRxiv · Oct 1, 2018Cancer Biology

Kinome rewiring reveals AURKA is a molecular barrier to the efficacy of PI3K/mTOR-pathway inhibitors in breast cancer

H. J. Donnella, J. T. Webber, R. S. Levin, R. Camarda, O. Momcilovic, N. Bayani, K. N. Shah, J. Korkola, K. M. Shokat, A. Goga, J. Gordan, S. Bandyopadhyay

The paper identifies AURKA as a barrier to PI3K/mTOR inhibitor efficacy in breast cancer by mapping kinome dynamics and showing that AURKA inhibition synergizes with these drugs to induce apoptosis and tumor regression.

bioRxiv · Jun 30, 2017Cancer Biology